Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB) (TAVAB)
Sponsor: Charite University, Berlin, Germany
Terminated
recruitment difficulties
Other terminated trials from Charite University, Berlin, Germany
- Inflammatory Cardiomyopathy · Phase PHASE2/PHASE3 · Apr 2025
- Heart Failure with Mid-range Ejection Fraction · Phase PHASE3 · Oct 2024
- Dream Disorder · Mar 2024
- Chronic Low-back Pain · Phase NA · Sep 2023
- Fertility Disorders · Phase NA · Dec 2022
See all terminations from Charite University, Berlin, Germany
Other Myasthenia Gravis trials with similar outcome
Listed as NCT02102594, this PHASE2 trial focuses on Myasthenia Gravis and Rheumatoid Arthritis and remains terminated or withdrawn. Sponsored by Charite University, Berlin, Germany, it has been updated 9 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2020 — Jan 2021 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Dec 2018 — Jan 2020 [monthly]
Recruiting PHASE2
▶ Show 4 earlier versions
-
Jun 2018 — Dec 2018 [monthly]
Recruiting PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Aug 2017 — Sep 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Aug 2017 [monthly]
Recruiting PHASE2
First recorded
Oct 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Charite University, Berlin, Germany
- NeuroCure Clinical Research Center, Charite, Berlin
- Prof. Dr. med. Falk Hiepe (Charité, Internal Medicine / Rheumathology)
For direct contact, visit the study record on ClinicalTrials.gov .